Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (145)	4/9/1999 12:15:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Mike, My sense is that the failure of one drug in an area hurts other companies in the same area (think sepsis as an extreme example). There's almost always room for more than one drug, as they invariably have different side-effects and indications. So I personally wouldn't see the Genentech failure as anything but a negative. NTII is the obvious play in the neuropathy area, but it's as much a play on their survival as on the drug. I've still got my NTII shares, and might be tempted to buy more if I could overcome my distaste at the spread. My guess is that REGN has bottomed out - I also bought a few shares recently at a little under $6. It's sort of an unusual beast - a depressed third tier without the usual finance risk. Peter